The data shown below were collected from the profiles of 281 X users who shared this research output. Click here to find out more about how the information was compiled.
As of 1 July 2024, you may notice a temporary increase in the numbers of X profiles with Unknown location. Click here to learn more.
You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output.
Click here to find out more.
X Demographics
Mendeley readers
Attention Score in Context
| Title |
The Grass Might Be Greener: Medical Marijuana Patients Exhibit Altered Brain Activity and Improved Executive Function after 3 Months of Treatment
|
|---|---|
| Published in |
Frontiers in Pharmacology, January 2018
|
| DOI | 10.3389/fphar.2017.00983 |
| Pubmed ID | |
| Authors |
Staci A. Gruber, Kelly A. Sagar, Mary K. Dahlgren, Atilla Gonenc, Rosemary T. Smith, Ashley M. Lambros, Korine B. Cabrera, Scott E. Lukas |
| Abstract |
The vast majority of states have enacted full or partial medical marijuana (MMJ) programs, causing the number of patients seeking certification for MMJ use to increase dramatically in recent years. Despite increased use of MMJ across the nation, no studies thus far have examined the specific impact of MMJ on cognitive function and related brain activation. In the present study, MMJ patients seeking treatment for a variety of documented medical conditions were assessed prior to initiating MMJ treatment and after 3 months of treatment as part of a larger longitudinal study. In order to examine the effect of MMJ treatment on task-related brain activation, MMJ patients completed the Multi-Source Interference Test (MSIT) while undergoing functional magnetic resonance imaging (fMRI). We also collected data regarding conventional medication use, clinical state, and health-related measures at each visit. Following 3 months of treatment, MMJ patients demonstrated improved task performance accompanied by changes in brain activation patterns within the cingulate cortex and frontal regions. Interestingly, after MMJ treatment, brain activation patterns appeared more similar to those exhibited by healthy controls from previous studies than at pre-treatment, suggestive of a potential normalization of brain function relative to baseline. These findings suggest that MMJ use may result in different effects relative to recreational marijuana (MJ) use, as recreational consumers have been shown to exhibit decrements in task performance accompanied by altered brain activation. Moreover, patients in the current study also reported improvements in clinical state and health-related measures as well as notable decreases in prescription medication use, particularly opioids and benzodiapezines after 3 months of treatment. Further research is needed to clarify the specific neurobiologic impact, clinical efficacy, and unique effects of MMJ for a range of indications and how it compares to recreational MJ use. |
X Demographics
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| United States | 72 | 26% |
| Canada | 22 | 8% |
| United Kingdom | 9 | 3% |
| Australia | 3 | 1% |
| Argentina | 3 | 1% |
| Chile | 3 | 1% |
| Comoros | 2 | <1% |
| Lebanon | 1 | <1% |
| Netherlands | 1 | <1% |
| Other | 12 | 4% |
| Unknown | 153 | 54% |
Demographic breakdown
| Type | Count | As % |
|---|---|---|
| Members of the public | 230 | 82% |
| Practitioners (doctors, other healthcare professionals) | 35 | 12% |
| Scientists | 12 | 4% |
| Science communicators (journalists, bloggers, editors) | 4 | 1% |
Mendeley readers
The data shown below were compiled from readership statistics for 131 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Unknown | 131 | 100% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Student > Ph. D. Student | 16 | 12% |
| Student > Bachelor | 16 | 12% |
| Researcher | 13 | 10% |
| Student > Master | 12 | 9% |
| Student > Doctoral Student | 12 | 9% |
| Other | 33 | 25% |
| Unknown | 29 | 22% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 21 | 16% |
| Psychology | 20 | 15% |
| Neuroscience | 12 | 9% |
| Biochemistry, Genetics and Molecular Biology | 6 | 5% |
| Pharmacology, Toxicology and Pharmaceutical Science | 6 | 5% |
| Other | 27 | 21% |
| Unknown | 39 | 30% |
Attention Score in Context
This research output has an Altmetric Attention Score of 377. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 03 May 2023.
All research outputs
#87,055
of 26,303,092 outputs
Outputs from Frontiers in Pharmacology
#26
of 20,200 outputs
Outputs of similar age
#2,079
of 456,888 outputs
Outputs of similar age from Frontiers in Pharmacology
#1
of 271 outputs
Altmetric has tracked 26,303,092 research outputs across all sources so far. Compared to these this one has done particularly well and is in the 99th percentile: it's in the top 5% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 20,200 research outputs from this source. They typically receive a little more attention than average, with a mean Attention Score of 5.5. This one has done particularly well, scoring higher than 99% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 456,888 tracked outputs that were published within six weeks on either side of this one in any source. This one has done particularly well, scoring higher than 99% of its contemporaries.
We're also able to compare this research output to 271 others from the same source and published within six weeks on either side of this one. This one has done particularly well, scoring higher than 99% of its contemporaries.